, with the Biologics License Application (BLA) number 125516 , is an orphan drug developed by United Therapeutics .
In European legal contexts, refers to a specific decision by the European Patent Office (EPO) Boards of Appeal regarding ZTE Corporation. 125516
It is typically administered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA). , with the Biologics License Application (BLA) number
It is specifically indicated for the treatment of pediatric patients with high-risk neuroblastoma . It is specifically indicated for the treatment of
It requires a 7V-9V DC input and uses specialized software like QuickEval-II (Pscope.exe) for data collection and analysis. 3. Legal & Intellectual Property: Case T 1255/16
On developer platforms like Stack Overflow , users with ID 125516 or similar numerical identifiers contribute to technical discussions regarding software like Visual Studio Code. T 1255/16 (Irregular LDPC code/ZTE) of 15.02.2019